VERIGRAFT
Private Company
Funding information not available
Overview
VERIGRAFT is a clinical-stage biotech pioneering a platform to create personalized, decellularized tissue grafts that are recellularized with the patient's own cells, potentially eliminating transplant rejection. The company is advancing a pipeline targeting chronic venous insufficiency (CVI), peripheral artery disease (PAD), nerve repair, and heart valve replacement, with its lead P-TEV program having reported first-in-human results. With a recent SEK 110 million capital commitment and a pivotal Phase II/III trial application submitted in Europe, VERIGRAFT is positioning to validate its technology in significant therapeutic areas with high unmet need.
Technology Platform
Proprietary platform for personalizing donor tissue grafts. Likely involves decellularization of donor tissue to create a scaffold, followed by recellularization with the patient's own cells to create a biocompatible, living graft designed to avoid immune rejection.
Opportunities
Risk Factors
Competitive Landscape
VERIGRAFT competes with developers of synthetic vascular grafts (e.g., Gore, BD), biological grafts (e.g., CryoLife), and other tissue engineering approaches. Its key differentiation is the personalization to avoid immunosuppression, a claim few others are pursuing clinically. In nerve repair, it competes with companies offering nerve guidance conduits.